A review of Johnson & Johnson’s COVID-19 adenovirus vector vaccine.

The verdict: The verdict (updated on August 24, 2021): Johnson & Johnson’s COVID-19 adenovirus vector vaccine was rather effective in phase-3 trials at preventing severe COVID-19. However, the real-life data show that the protection is short-lived, limited to 2 to 7 months after vaccination. The single-dose Johnson and Johnson vector vaccine creates the shortest period of protection. None of the intramuscular vaccines against COVID-19 limit transmission.
For the most vulnerable groups, in particular, people of advanced age who can not take other prevention, hygiene, prophylaxis, and early treatment measures, Astra-Zeneca-Oxford vector vaccine, two doses, may be a somewhat better option. Tens of thousands of people of advanced age vaccinated in Scotland apparently survived vaccination with Astra-Zeneca-Oxford. Adverse effects of Astra-Zeneca-Oxford vaccine are less pronounced than in younger groups. For younger people, and competent literate normal people of all ages, we do NOT recommend Astra-Zeneca-Oxford vaccine (as of August 2021).

Fauci, a strange 79 years old character, who has been involved in sabotage for over 30 years, suddenly warns about a real concern: vaccines often cause antibody-dependent enhancement (ADE) of the infection.

Fauci, a strange 79 years old character, who has been involved in sabotage for over 30 years, suddenly warns COVID-19 vaccines can be dangerous.

Use this video with Fauci to influence brainwashed sheep. The main danger today is if bureaucracy makes it compulsory to get vaccinated with ineffective and unsafe vaccines.

The propaganda machine, idiotic bureaucrats and "scholars" say that an impossible injectable snake oil is the ultimate solution for COVID-19.

Hepatitis B vaccine: only 25% of adults aged above 40 developed antibodies. 75% remained unprotected.

Another ineffective vaccine: hepatitis B.
“The proportions of people who were protected after vaccination was 26.0%…”

On April 24, 2020, the World Health Organization, a globalist bureaucratic entity involved in a lot of sabotage and disinformation, unexpectedly came up with a criticism of the idea of the "immunity passports".

A rare good move: the World Health Organization criticized “immunity passports” (April 24, 2020).

COVID-19 “immunity passports” is another Nazi-style idea. It is good that the WHO criticized COVID-19 “immunity passports”.

Researcher Stanley Perlman studies coronaviruses and he is brighter than the average. On the photo, he is with his co-author. Rudragouda Channappanavar Stanley Perlman.

T cell-mediated immune response to respiratory coronaviruses and vaccines against SARS-CoV that induce immunopathology.

A 2011 study: A vaccine against SARS-CoV-1 provides incomplete protection in mice and induces increased eosinophilic proinflammatory response in lungs.

The brainwashed masses are ready to inject themselves with anything. But will vaccines work in those who are in the high-risk group, that is, people aged 70 and older? It is unlikely. According to a 2006 study by Corsini et al., the currently available influenza vaccines do not work in 70% of those aged 70 to 80 do develop antibodies after a flu vaccination. Among those aged 80 and above, 90% do not develop antibodies after a flu vaccine administration.

COVID-19 vaccines are unlikely to protect those who are at a higher risk. A 2006 study: Vaccines fail to generate protective immunity in 50% to 90% of older individuals.

Seroconversion after a vaccine is 50% from 60 to 70 years old, 31% from 70 to 80 years old, and only 11% after the age of 80.
Conclusions: Billions are being spent on COVID-19 vaccines that are unlikely to work in the highest-risk group, those aged 70 and above.

Fig. 2. Model of immunopathological events associated with SARS clinical evolution. SARS patients mount robust IFN-mediated innate immune responses during early (acute) illness and peak symptomology. Following the median SO2 nadir in surviving patients (late SARS), most SARS patients resolve inflammation and mount effective adaptive immunity against SARS CoV. Immune dysregulation in severe SARS patients is hallmarked by continued expression of inflammatory chemokines and ISGs and deficiencies in MHC and Ig gene expression. Immune-mediated pathology worsens in the minority of susceptible SARS patients and unresolved CXCL10 expression and viral burden is associated with poor outcome. Source: Cameron, 2007.

There is an antibody-dependent enhancement (ADE) of SARS-CoV-1 infection. Notably, some vaccines enhance infection.

Some vaccines against animal coronaviruses have been successfully generated, but their development has proven very difficult due to immune enhancement of disease in vaccinated recipients (28, 53, 65).